- Home
- KYTX vs AMRN Comparison
KYTX vs AMRN Comparison
Compare KYTX & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- AMRN
- Stock Information
- Founded
- KYTX 2018
- AMRN 1989
- Country
- KYTX United States
- AMRN Ireland
- Employees
- KYTX N/A
- AMRN N/A
- Industry
- KYTX
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- KYTX
- AMRN Health Care
- Exchange
- KYTX NYSE
- AMRN Nasdaq
- Market Cap
- KYTX 242.1M
- AMRN 248.6M
- IPO Year
- KYTX 2024
- AMRN 1993
- Fundamental
- Price
- KYTX $5.29
- AMRN $0.57
- Analyst Decision
- KYTX Buy
- AMRN Hold
- Analyst Count
- KYTX 4
- AMRN 2
- Target Price
- KYTX $23.25
- AMRN N/A
- AVG Volume (30 Days)
- KYTX 262.9K
- AMRN 914.3K
- Earning Date
- KYTX 11-15-2024
- AMRN 10-30-2024
- Dividend Yield
- KYTX N/A
- AMRN N/A
- EPS Growth
- KYTX N/A
- AMRN N/A
- EPS
- KYTX N/A
- AMRN N/A
- Revenue
- KYTX N/A
- AMRN $241,021,000.00
- Revenue This Year
- KYTX N/A
- AMRN N/A
- Revenue Next Year
- KYTX N/A
- AMRN N/A
- P/E Ratio
- KYTX N/A
- AMRN N/A
- Revenue Growth
- KYTX N/A
- AMRN N/A
- 52 Week Low
- KYTX $4.40
- AMRN $0.56
- 52 Week High
- KYTX $30.60
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- KYTX 49.62
- AMRN 45.27
- Support Level
- KYTX $4.78
- AMRN $0.56
- Resistance Level
- KYTX $5.61
- AMRN $0.64
- Average True Range (ATR)
- KYTX 0.36
- AMRN 0.04
- MACD
- KYTX 0.06
- AMRN -0.00
- Stochastic Oscillator
- KYTX 57.45
- AMRN 14.80
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.